Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma

被引：12

作者：

Han, Ji Won ^{[1
,2
]}

Jang, Jeong Won ^{[1
,2
]}

机构：

[1] Catholic Univ Korea, Catholic Univ Liver Res Ctr, Coll Med, Seoul 06591, South Korea

[2] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Gastroenterol & Hepatol, Seoul 06591, South Korea

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 14期

基金：

新加坡国家研究基金会;

关键词：

hepatocellular carcinoma; atezolizmumab-bevacizumab; biomarker; NEUTROPHIL-LYMPHOCYTE RATIO; PLUS BEVACIZUMAB; TUMOR; EXPRESSION; CELLS; INTERLEUKIN-6; MULTICENTER; COMBINATION; SUPPRESSION; SORAFENIB;

D O I：

10.3390/ijms241411799

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A combination of atezolizumab with bevacizumab (AB) is the first regimen that has shown superiority compared to sorafenib and is now being used as the systemic treatment of choice for hepatocellular carcinoma (HCC) patients with Barcelona Liver Cancer Clinic stage C. However, a considerable number of patients do not achieve survival or significant responses, indicating the need to identify predictive biomarkers for initial and on-treatment decisions in HCC patients receiving AB. In this manuscript, we summarized the current data from both experimental and clinical studies. This review will be beneficial for both clinicians and researchers in clinical practice as well as those designing experimental, translational, or clinical studies.

引用

页数：22

共 122 条

[1] Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody [J].

Akce, Mehmet ;

Liu, Yuan ;

Zakka, Katerina ;

Martini, Dylan J. ;

Draper, Amber ;

Alese, Olatunji B. ;

Shaib, Walid L. ;

Wu, Christina ;

Wedd, Joel P. ;

Sellers, Marty T. ;

Bilen, Mehmet A. ;

El-Rayes, Bassel F. .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (02) :74-81

[2] Circulating Cytokines Reflect the Etiology-Specific Immune Environment in Cirrhosis and HCC [J].

Beudeker, Boris J. B. ;

Groothuismink, Zwier M. A. ;

van der Eijk, Annemiek A. ;

Debes, Jose D. ;

Boonstra, Andre .

CANCERS, 2022, 14 (19)

[3] Autocrine Human Growth Hormone Promotes Tumor Angiogenesis in Mammary Carcinoma [J].

Brunet-Dunand, Severine E. ;

Vouyovitch, Cecile ;

Araneda, Silvia ;

Pandey, Vijay ;

Vidal, Laurent J. -P. ;

Print, Cristin ;

Mertani, Hichem C. ;

Lobie, Peter E. ;

Perry, Jo K. .

ENDOCRINOLOGY, 2009, 150 (03) :1341-1352

[4] Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma: Relationship With Clinical and Pathological Features [J].

Calderaro, Julien ;

Rousseau, Benoit ;

Amaddeo, Giuliana ;

Mercey, Marion ;

Charpy, Cecile ;

Costentin, Charlotte ;

Luciani, Alain ;

Zafrani, Elie-Serge ;

Laurent, Alexis ;

Azoulay, Daniel ;

Lafdil, Fouad ;

Pawlotsky, Jean-Michel .

HEPATOLOGY, 2016, 64 (06) :2038-2046

[5] Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab [J].

Campani, Claudia ;

Bamba-Funck, Jessica ;

Campion, Bertille ;

Sidali, Sabrina ;

Blaise, Lorraine ;

Ganne-Carrie, Nathalie ;

Demory, Alix ;

Sutter, Olivier ;

Larrey, Edouard ;

Evain, Manon ;

Ghannouchi, Haroun ;

Wagner, Mathilde ;

Marra, Fabio ;

Sutton, Angela ;

Allaire, Manon ;

Nault, Jean-Charles .

LIVER INTERNATIONAL, 2023, 43 (03) :708-717

[6] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) [J].

Chan, L. S. ;

Kudo, M. ;

Sangro, B. ;

Kelley, R. K. ;

Furuse, J. ;

Park, J-W. ;

Sunpaweravong, P. ;

Fasolo, A. ;

Yau, T. ;

Kawaoka, T. ;

Cheng, A-L. ;

Azevedo, S. ;

Reig Monzon, M. E. ;

Assenat, E. ;

Yarchoan, M. ;

He, A. R. ;

Makowsky, M. ;

Ran, D. ;

Negro, A. ;

Abou-Alfa, G. K. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S869-S870

[7] Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study [J].

Chan, Stephen Lam ;

Yip, Terry Cheuk-Fung ;

Wong, Vincent Wai-Sun ;

Tse, Yee-Kit ;

Yuen, Becky Wing-Yan ;

Luk, Hester Wing-Sum ;

Lui, Rashid Nok-Shun ;

Chan, Henry Lik-Yuen ;

Mok, Tony Shu-Kam ;

Wong, Grace Lai-Hung .

CANCER MEDICINE, 2020, 9 (19) :7052-7061

[8] Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer [J].

Chen, Z-Y ;

Raghav, K. ;

Lieu, C. H. ;

Jiang, Z-Q ;

Eng, C. ;

Vauthey, J-N ;

Chang, G. J. ;

Qiao, W. ;

Morris, J. ;

Hong, D. ;

Hoff, P. ;

Tran, H. ;

Menter, D. G. ;

Heymach, J. ;

Overman, M. ;

Kopetz, S. .

BRITISH JOURNAL OF CANCER, 2015, 112 (06) :1088-1097

[9]

Cheng AL, 2022, J HEPATOL, V76, P862, DOI [10.1016/j.jhep.2021.11.030, 10.1016/j.jceh.2022.07.003]

[10] Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment [J].

Chon, Young Eun ;

Cheon, Jaekyung ;

Kim, Hyeyeong ;

Kang, Beodeul ;

Ha, Yeonjung ;

Kim, Do Young ;

Hwang, Seong Gyu ;

Chon, Hong Jae ;

Kim, Beom Kyung .

CANCER MEDICINE, 2023, 12 (03) :2731-2738

← 1 2 3 4 5 6 7 8 9 10 →